

【2024年】

1. Fujii T, Murata K, Onizawa H, Onishi A, Tanaka M, Murakami K, Nishitani K, Furu M, Watanabe R, Hashimoto M, Ito H, Fujii T, Mimori T, Morinobu A, Matsuda S. Management and treatment outcomes of rheumatoid arthritis in the era of biologic and targeted synthetic therapies: evaluation of 10-year data from the KURAMA cohort. *Arthritis Res Ther.* 2024;26(1):16. doi: 10.1186/s13075-023-03251-z. PMID: 38195572 [Epub ahead of print]
2. Abe Y, Fujii T, Miyawaki Y, Sugihara T, Uchida HA, Maejima Y, Watanabe Y, Hashimoto T, Miyamae T, Nakaoka Y, Harigai M, Tamura N. Real-world clinical decisions of physicians in the management of Takayasu arteritis and giant cell arteritis in Japan: A cross-sectional web questionnaire survey. *Mod Rheumatol.* 2024;34(6):1194-1201. doi:10.1093/mr/roae034. PMID: 38590042
3. Katsumata Y, Sada KE, Kameda T, Dobashi H, Kaname S, Tsuboi N, Matsumoto Y, Amano K, Tamura N, Harigai M; Members of the Research Committee of Intractable Vasculitis Syndrome and the Research Committee of Intractable Renal Disease of the Ministry of Health, Labour and Welfare of Japan (Fujii T): In addition to the authors, the following investigators and institutions participated in this study. Comparison of different ANCA detection methods in a predominantly MPO-ANCA-associated vasculitis cohort. *Immunol Med.* 2024. doi: 10.1080/25785826.2024.2408054. PMID: 39391948.[Epub ahead of print]
4. Kawajiri T, Iwata S, Tanaka K, Sonoda T, Nishikawa M, Iwamoto R, Takahashi Y, Kojima F, Fujii T. Granulomatosis with polyangiitis with lacrimal gland enlargement and pancreatic swelling: case report and literature review. *Mod Rheumatol Case Rep.* 2024. doi: 10.1093/mrcr/txae066. PMID: 39440997. [Epub ahead of print]
5. Okamoto N, Atsumi T, Takagi M, Takahashi N, Takeuchi T, Tamura N, Nakajima A, Nakajima A, Fujii T, Matsuno H, Ishii T, Tsujimoto N, Nishikawa A, Minatoya M, Tanaka Y, Kuwana M. Safety of baricitinib in Japanese patients with rheumatoid arthritis in clinical use: 3-year data of all-case post-marketing surveillance study. *Mod Rheumatol.* 2024. doi: 10.1093/mr/roae064. PMID: 39119689. [Epub ahead of print]
6. Yoshida M, Iwata S, Tabata K, Hashimoto A, Matsumiya R, Tanaka K, Iwamoto R, Jinnin M, Fujii T. MPO- ANCA-positive eosinophilic granulomatosis with polyangiitis complicated by alveolar hemorrhage treated with mepolizumab as an induction therapy: Case report. *Mod Rheumatol Case Rep.* in press.
7. Ueno M, Iwata S, Yamagata K, Todoroki Y, Sonomoto K, Miyagawa I, Kubo S, Miyazaki Y, Hiroko Miyata H, Nagayasu A, Kanda R, Aritomi T, Nakayamada S, Tanaka Y. The induction of interleukin-21 receptor expression via enhanced intracellular metabolism in B cells and its relevance to the disease activity in systemic lupus erythematosus. *RMD open.* in press.
8. Tanaka Y, Miyazaki Y, Hirata S, Kusaka K, Kosaka S, Nakatsuka K, Saito K, Iwata S, Yamaguchi Y, Yabe-Wada T, Fujiwara M, Arita Y, Hoshino M, Ozaki N, Yamaoka K, Nakayamada S. Impact of quality of life on overall work productivity impairment and activity impairment of patients with systemic lupus erythematosus: the PEONY study. *Lupus Sci Med.* in press

【2023 年】

1. Miyawaki Y, Fujii T, Anan K, Kodera M, Kikuchi M, Sada KE, Nagasaka K, Bando M, Sugiyama H, Kaname S, Harigai M, and Tamura N. Concordance between practice and published evidence in the management of ANCA-associated vasculitis in Japan: A cross-sectional web-questionnaire survey. *Mod Rheumatol.* 2023 33(5):990-997 DOI: 10.1093/mr/roac118. PMID:36181464.
2. Yaku A, Ishikawa Y, Iwasaki T, Hiwa R, Matsuo K, Saji H, Yurugi K, Miura Y, Furu M, Ito H, Fujii T, Maekawa T, Hashimoto M, Ohmura K, Mimori T, and Terao C. Genetic architecture underlying IgG-RF production is distinct from that of IgM-RF. *Rheumatology (Oxford).* 2023;62:2015–2020.
3. Tane M, Kosako H, Hosoi H, Tabata K, Hiroi T, Osawa K, Iwamoto R, Murata S, Mushino T, Murata SI, Araki SI, Fujii T, and Sonoki T. Severe systemic inflammation mimicking TAFRO syndrome following COVID-19. *Int J Hematol.* 2023; doi: 10.1007/s12185-023-03589-9. PMID: 37000328.[Epub ahead of print]
4. Harigai M, Fujii T, Sakai R, Igarashi A, Shoji A, Yamaguchi H, Iwasaki K, Makishima M, Yoshida A, Okada N, Yamashita K, and Kawahito Y. Risk of hospitalized infections in older elderly patients with rheumatoid arthritis treated

with tocilizumab or other biological/targeted synthetic disease-modifying antirheumatic drugs: Evaluation of data from a Japanese claims database. *Mod Rheumatol*. 2023; doi: 10.1093/mr/road031. PMID: 37039670.

5. Kuwana M, Bando M, Kawahito Y, Sato S, Suda T, Kondoh Y, and CTD-ILD Delphi Collaborators (Fujii T). Identification and management of connective tissue disease associated interstitial lung disease: evidence-based Japanese consensus statements. *Expert Rev Respir Med*. 2023;17(1):71-80.
6. Kameda H, Yamaoka K, Yamanishi Y, Tada M, Koike R, Nakajima A, Fusama M, Fujii T. Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: Secondary publication. *Mod Rheumatol*. 2023. Epub 20231011. doi: 10.1093/mr/road098. PubMed PMID: 37819199.
6. Kuwana M, Sugiyama N, Momohara S, Atsumi T, Takei S, Tamura N, Harigai M, Fujii T, Matsuno H, Takeuchi T, Yamamoto K, Takasaki Y, Tanigawa M, Endo Y, Hirose T, Morishima Y, Yoshii N, Mimori T, Takagi M. Six-month safety and effectiveness of tofacitinib in patients with rheumatoid arthritis in Japan: Interim analysis of post-marketing surveillance. *Mod Rheumatol*. 2023. Epub 20230703. doi: 10.1093/mr/road063. PubMed PMID: 37405710.
7. Miyata H, Sonomoto K, Fukuyo S, Nakayamada S, Nakano K, Iwata S, Miyazaki Y, Kawabe A, Aoki T, Tanaka Y. Computed tomography for malignancy screening in patients with rheumatoid arthritis before initiation of disease modifying antirheumatic drug. *Rheumatology (Oxford)*. 62(10):3339-3349. ead075. 2023
8. Fujita Y, Iwata S, Hidese S, Ishiwata S, Ide S, Tanaka H, Sonomoto K, Miyazaki Y, Nakayamada S, Ikenouchi A, Hattori K, Kunugi H, Yoshimura R, Tanaka Y. Reduced homovanillic acid, SDF-1 α and SCGF- β levels in cerebrospinal fluid are related to depressive states in systemic lupus erythematosus. *Rheumatology (Oxford)*. 62(10):3490-3500. ead091. 2023
9. Sonomoto K, Nakayamada S, Fujino Y, Miyata H, Kubo S, Fujita Y, Inoue Y, Matsunaga S, Iwata S, Hanami K, Todoroki Y, Yoshinari-Korekoda H, Kawabe A, Yamaguchi A, Ueno M, Satoh-Kanda Y, Kanda R, Funada M, Ohkubo N, Kusaka K, Kosaka S, Nagayasu A, Fukuyo S, Nawata M, Miyazaki Y, Tokunaga M, Tanaka K, Okada Y, Tanaka Y. Biological/targeted synthetic DMARDs do not arrest bone loss in patients with rheumatoid arthritis: a multicenter prospective observational study. *Rheumatology (Oxford)*. ead579. 2023
10. Kusaka K, Nakayamada S, Iwata S, Tanaka Y. Evaluation of asymptomatic cerebral ischemia by arterial spin-labeling magnetic resonance imaging of the brain in Takayasu arteritis. *Rheumatology (Oxford)*. 62(7):e235-e236. 2023
11. Iwata S, Hajime Sumikawa M, Tanaka Y. B cell activation via immunometabolism in systemic lupus erythematosus. *Front Immunol*. 14:1155421. 2023

【2022 年】

1. Tabata K, Kaminaka C, Yasutake M, Matsumiya R, Inaba Y, Yamamoto Y, Jinnin M and Fujii T. Forearm porphyrin levels evaluated by digital imaging system are increased in patients with systemic sclerosis compared with patients in pre-clinical stage. *Intractable Rare Dis Res*. 2022 ; 11(1):1-6.
2. Takagi M, Atsumi T, Matsuno H, Tamura N, Fujii T, Okamoto N, Takahashi N, Nakajima A, Nakajima A, Tsujimoto N, Nishikawa A, Ishii T, Takeuchi T, and Kuwana M. Safety and effectiveness of baricitinib for rheumatoid arthritis in Japanese clinical practice: 24-week results of all-case post-marketing surveillance. *Mod Rheumatol*. 2022. DOI :10.1093/mr/roac089. PMID: 35932218. [Epub ahead of print]
3. Kuramoto N, Saito S, Fujii T, Kaneko Y, Saito R, Tanaka M, Takada H, Nakano K, Saito K, Sugimoto N, Sasaki S, Harigai M, and Suzuki Y. Characteristics of rheumatoid arthritis with immunodeficiency-associated lymphoproliferative disorders to regress spontaneously by the withdrawal of methotrexate and their clinical course: A retrospective, multicenter, case control study. *Mod Rheumatol*. 2022; 32(1):24-31.
4. Takada H, Kaneko Y, Nakano K, Tanaka M, Fujii T, Saito K, Sugimoto N, Sasaki S, Saito S, Saito R, Kuramoto N, Harigai M, and Suzuki Y. Clinicopathological characteristics of lymphoproliferative disorders in 232 patients with rheumatoid arthritis in Japan: A retrospective, multicenter, descriptive study. *Mod Rheumatol*. 2022; 32(1):32-40.
5. Nakano K, Tanaka Y, Saito K, Kaneko Y, Saito S, Tanaka M, Saito R, Fujii T, Kuramoto N, Sugimoto N, Takada H, Harigai M, Sasaki S, and Suzuki Y. Treatment of rheumatoid arthritis after regression of lymphoproliferative disorders in patients treated with methotrexate: a retrospective, multi-center descriptive study. *Mod Rheumatol* 2022; 32(1):41-49.

6. Saito R, Tanaka M, Ito H, Kuramoto N, Fujii T, Saito S, Kaneko Y, Nakano K, Saito K, Takada H, Sugimoto N, Sasaki S, Harigai M, and Suzuki Y. Overall survival and post-spontaneous regression relapse-free survival of patients with lymphoproliferative disorders associated with rheumatoid arthritis: A multi-center retrospective cohort study. *Mod Rheumatol*. 2022; 32(1):50-58.
7. Shen M, Wang D, Sennari Y, Zeng Z, Baba R, Morimoto H, Kitamura N, Nakanishi T, Tsukada J, Ueno M, Todoroki Y, Iwata S, Yonezawa, Tanaka Y, Osada Y, Yoshida Y. Pentacyclic triterpenoid ursolic acid induces apoptosis with mitochondrial dysfunction in adult T-cell leukemia cells to promote surrounding cell growth. *Med Oncol*. 39(8):118. 2022
8. Miyagawa I, Nakayamada S, Ueno M, Miyazaki Y, Iwata S, Kubo S, Sonomoto K, Anan J, Ohkubo N, Inoue Y, Tanaka Y. Impact of serum interleukin 22 as a biomarker for the differential use of molecular targeted drugs in psoriatic arthritis: A retrospective study. *Arthritis Res Ther*. 24(1):86. 2022
9. Ueno M, Miyagawa I, Aritomi T, Kimura K, Iwata S, Hanami K, Fukuyo S, Kubo S, Miyazaki Y, Nakayamada S, and Tanaka Y. Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study. *Arthritis Res Ther*. 24(1):159. 2022
10. Nguyen AP, Yamagata K, Iwata S, Trimova G, Zhang T, Shan Y, Nguyen MP, Sonomoto K, Nakayamada S, Kato S, Tanaka Y. Enhancer RNA commits osteogenesis via microRNA-3129 expression in human bone marrow-derived mesenchymal stem cells. *Inflamm Regen*. 42(1):43. 2022
11. Yamagata K, Nakayamada S, Zhang T, Nguyen AP, Ohkubo N, Iwata S, Kato S, Tanaka Y. IL-6 production through repression of UBASH3A gene via epigenetic dysregulation of super-enhancer in CD4⁺ T cells in rheumatoid arthritis. *Inflamm Regen*. 2022;42(1):46. 2022
12. Zhang T, Yamagata K, Iwata S, Sonomoto K, Trimova G, Nguyen AP, Hao H, Shan Y, Nguyen MP, Nakayamada S, Tanaka Y. Epstein-Barr virus-induced gene 3 commits human mesenchymal stem cells to differentiate into chondrocytes via endoplasmic reticulum stress sensor. *PLoS One*. 17(12):e0279584. 2022
13. Fujita Y, Iwata S, Nakano K, Nakayamada S, Miyazaki Y, Kawabe A, Korekoda-Yoshinari H, Nawata A, Tanaka Y. A case of simultaneous onset of highly active systemic lupus erythematosus and IgG4-related renal disease. *Modern Rheumatology Case Reports*. 6(2):178-182. 2022
14. Kanda R, Nakano K, Nawata A, Iwata S, Nakayamada S, Tanaka Y. Remission of Granulomatosis with Polyangiitis Only After Resection of Pulmonary Nodule; A case report. *Intern Med*. 61(18):2803-2808. 2022
15. Iwata S, Tanaka Y. Association of viral infection with the development and pathogenesis of systemic lupus erythematosus. *Front Med (Lausanne)*. 25:9:849120. 2022.
16. Sumikawa HM, Iwata S, Zhang M, Miyata H, Ueno M, Todoroki Y, Nagayasu A, Kanda R, Sonomoto K, Torimoto K, Lee S, Nakayamada S, Yamamoto K, Okada Y, Tanaka Y. An enhanced mitochondrial function through glutamine metabolism in plasmablast differentiation in systemic lupus erythematosus. *Rheumatology (Oxford)*. 2022 Jul 6;61(7):3049-3059.
17. Ohkubo N, Iwata S, Nakano K, Miyagawa I, Hanami K, Fukuyo S, Miyazaki Y, Kawabe A, Nakayamada S, Tanaka Y. Efficacy and safety of high-dose of mycophenolate mofetil compared with cyclophosphamide pulse therapy as induction therapy in Japanese patients with proliferative lupus nephritis. *Mod Rheumatol*. 2022 Oct 15;32(6):1077-1085.
18. Inoue Y, Nakayamada S, Kubo S, Yamagata K, Sonomoto K, Iwata S, Miyazaki Y, Tanaka Y. T helper cells expressing fractalkine receptor and bearing T follicular helper 1-like cell functions in patients with IgG4-related disease. *Rheumatology (Oxford)*. 2022 Aug 30;61(9):3854-3863.
19. Miyazaki Y, Nakayamada S, Sonomoto K, Kawabe A, Inoue Y, Okubo N, Iwata S, Hanami K, Tanaka Y. Efficacy and safety of belimumab during maintenance therapy in patients with systemic lupus erythematosus. *Rheumatology (Oxford)*. 2022 Aug 30;61(9):3614-3626.

【2021 年】

1. Tabata K, Jinnin M, Furukawa K, Tani S, Okuhira H, Mikita N, and Fujii T. Finger sweating levels evaluated by video capillaroscopy system are increased in patients with systemic sclerosis compared to pre-clinical stage patients. *Drug Discoveries & Therapeutics*. 2021;14(6):325-329.

2. Yoshifuji H, Kagebayashi S, Kinoshita H, Fujii T, Okano Y, Katsushima M, and Mimori T. A case of pulmonary arterial hypertension complicated by anti-neutrophil cytoplasmic antibody-associated vasculitis and systemic sclerosis. *Immunol Med.* 2021;44(4):263-269.